US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Terminated

Adcetris 96 MG/100 ML NS IVPB

Reason Lack of Assurance of Sterility

Infusion Options, Inc. D-1746-2019
Class II · Moderate risk Terminated

Abraxane 170 MG / 34 ML IVPB

Reason Lack of Assurance of Sterility

Infusion Options, Inc. D-1745-2019
Class II · Moderate risk Terminated

Robafen DM

Reason CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Preferred Pharmaceuticals, Inc NDC 68788-0841-01 D-1410-2019
Class I · High risk Terminated

Hydromorphone HCl in 0.9% sodium chloride

Reason Incorrect Product Formulation; Firm's customer resource center (CRC) statement indicates that the product is sulfite free, however the product is produced with a raw material that contains sulfite

PharMEDium Services, LLC NDC 61553-352-78 D-1488-2019
Class III · Low risk Terminated

Myorisan

Reason Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.

Akorn Inc NDC 61748-304-13 D-1392-2019
Class II · Moderate risk Ongoing

LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles

Reason CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Teva Pharmaceuticals USA NDC 00591-3747-00 D-1456-2019
Class II · Moderate risk Terminated

Cetirizine Oral Solution 1 mg/mL

Reason cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

P & L Developments, LLC NDC 11673-178-04 D-1409-2019
Class II · Moderate risk Terminated

Cetirizine Oral Solution 1 mg/mL

Reason cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

P & L Developments, LLC NDC 63868-430-04 D-1408-2019
Class II · Moderate risk Terminated

Cetirizine HCL Oral Solution 1 mg/mL

Reason cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

P & L Developments, LLC NDC 55910-878-04 D-1407-2019
Class II · Moderate risk Terminated

Wal-Fex D Fexofenadine HCl 60 mg/ Pseudoephedrine HCl 120 mg

Reason Testing of Fexofenadine HCl and Pseudoephedrine Failed Impurities/Degradation Specifications: elevated substance results that were reported above or near the specification limit

Sun Pharmaceutical Industries, Inc. D-1390-2019